Treatment for primary postpartum haemorrhage.

Area of Science:

• Obstetrics and Gynecology
• Maternal Health
• Pharmacology

Background:

• Primary postpartum hemorrhage (PPH) is a leading cause of maternal mortality globally.
• Effective management strategies for PPH are crucial for reducing maternal morbidity and mortality.

Purpose of the Study:

• To evaluate the efficacy and safety of pharmacological, surgical, and radiological interventions for primary PPH.
• To synthesize evidence from randomized controlled trials on PPH treatments.

Main Methods:

• Systematic search of the Cochrane Pregnancy and Childbirth Group's Trials Register.
• Inclusion of randomized controlled trials comparing pharmacological, surgical, and radiological interventions for PPH.
• Independent assessment of study eligibility, quality, and data extraction.

Main Results:

• Misoprostol (600-1000 mcg) did not significantly reduce maternal mortality, hysterectomy, need for additional uterotonics, blood transfusion, or retained products.
• Misoprostol use was associated with increased maternal pyrexia and shivering.
• One trial suggested rectal misoprostol might be effective compared to oxytocin/ergometrine, but evidence was limited.

Conclusions:

• Insufficient evidence supports misoprostol's superiority over standard uterotonics for primary PPH.
• Large, multi-center, double-blind randomized controlled trials are needed to determine optimal uterotonic combinations, routes, and dosages.
• Further research is required to establish best practices for managing PPH unresponsive to initial uterotonic therapy.